Unlock instant, AI-driven research and patent intelligence for your innovation.

N,N-disubstituded amide for inhibit binding of integrins to their receptors protein

An integer, compound technology, applied in the field of compounds that inhibit this combination, can solve problems such as runaway, white blood cell overflow, tissue damage, etc.

Inactive Publication Date: 2001-07-25
TEXAS BIOTECH
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although the migration of white blood cells to the site of injury helps fight infection and destroy foreign material, in many cases this migration becomes uncontrolled and white blood cells flood the site of injury causing extensive tissue damage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0108] Methods of preparing liposomes are known in the art. See, eg, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 etseq.

[0109] The term "pharmaceutically acceptable prodrugs" as used herein means prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with human and lower animal tissues without undue toxicity, irritation Sex, allergic reaction, etc., with a reasonable benefit / risk ratio, effective for its intended use, and if possible, the zwitterionic form of the compounds of the invention. The prodrugs of the present invention can be rapidly converted in vivo to the parent compound of the above general formula by, for example, hydrolysis in blood. In T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V.14 of the A.C.S. Symposium Series and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Assoc...

Embodiment 1

[0121]Example 1 (9S, 13S)-13-(1,3-benzodioxol-5-yl)-9-{[benzyl (2-thienylmethyl)amino]carbonyl}-3 , Synthetic Step 1 of 11-dioxo-1-phenyl-2-oxa-4,10,12-triazpentadecane-15-acid (6): Thiophene-2-methylamine (1.36 ml, 13.26mmol) was dissolved in methanol (20mL). To this solution were added benzaldehyde (1.34 mL, 13.26 mmol), sodium cyanoborohydride (832 mg, 13.26 mmol) and 2 drops of acetic acid. The reaction was stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure, then dissolved in ethyl acetate (500ml). The organic layer was washed with water (200ml), saturated sodium bicarbonate (200ml) and brine (200ml). The organic solution was dried over magnesium sulfate and concentrated under reduced pressure. The residue was washed with silica gel and eluted with ethyl acetate:hexane (1:3) to obtain compound 1 (1.305 g, 48%). Step 2: Dissolve compound 1 (50mg, 0.246mmol) and Na-BOC-Ne-Cbz-L-lysine (94mg, 0.246mmol) in DMF (3ml), ad...

Embodiment 23

[0122] Example 23-({[((1S)-1-{[benzyl(2-thienylmethyl)amino]carbonyl}pentyl)amino]carbonyl}amino)-3-(4-butoxyphenyl ) Synthetic step 1 of propionic acid (12): (1S,2R,5S)-(+)menthyl (R)-p-toluenesulfinate (0.59g, 2.0mmol) was dissolved in THF (5ml), and cooled to -78°C under a nitrogen atmosphere. Treat by dropwise addition of lithium N,N-bis(trimethylsilyl)amide (3.0 ml, 1.0 M in THF). After the addition was complete, the cooling bath was removed and the mixture was stirred at room temperature for 5 hours. The solution was cooled to 0°C and thiophene-2-carbaldehyde (0.37ml, 4.0mmol) was added via syringe, followed rapidly by cesium fluoride powder (0.61g, 4.0mmol). The resulting suspension was stirred at room temperature for 18 hours. The reaction was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic phase was washed with brine and dried over sodium sulfate. The organic solution was filtered and concentrated under reduced pres...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for the inhibition of the binding of alpha 4 beta 1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which alpha 4 beta 1 is involved.

Description

[0001] This application is a continuation-in-part of pending US provisional application 60 / 082019 filed April 16,1998. field of invention [0002] The present application is generally concerned with the inhibition of integrin binding to its receptors such as VCAM-1 (vascular cell adhesion molecule-1) and fibronectin. The present invention also relates to compounds that inhibit this combination; pharmaceutically active compositions containing the compounds; and the compounds described above or in the control or prevention of alpha 4 beta 1 Applications in the preparation of diseases. Background of the invention [0003] White blood cells, also called leukocytes, play a major role in the inflammatory response when tissues are invaded or damaged by microorganisms. One of the most important aspects of the inflammatory response involves cell adhesion. Normally, white blood cells are found throughout the blood circulation. However, when tissue becomes infected or damaged, whit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D317/44A61K31/16A61K31/357A61K31/36A61K31/38A61K31/381A61K31/404A61K31/4184A61K31/425A61K31/427A61K31/443A61K31/4433A61K31/4525A61K31/495A61K31/496A61K31/5377A61P1/04A61P3/10A61P9/10A61P11/06A61P17/00A61P19/02A61P25/00A61P29/00A61P35/00A61P35/02A61P37/06A61P37/08A61P43/00C07C233/00C07D233/02C07D277/30C07D317/60C07D333/20C07D333/24C07D333/36C07D405/00C07D405/12C07D405/14C07D409/00C07D409/12C07D409/14C07D413/14C07D417/14
CPCC07D333/20C07D317/60C07D413/14C07D333/24C07D405/14C07D417/14C07D409/12C07D409/14A61P1/04A61P11/06A61P17/00A61P19/02A61P25/00A61P29/00A61P35/00A61P35/02A61P37/06A61P37/08A61P43/00A61P9/00A61P9/10A61P3/10
Inventor J·M·卡西尔R·J·比迪格尔V·O·格拉贝S·林R·V·马克特B·G·拉朱I·L·斯科特T·P·科甘
Owner TEXAS BIOTECH